Who/When to Treat Clinically Suspect Arthralgia Dr. Jack Cush discusses risk stratification in Clinically suspect arthralgia; referencing EULAR2025 abstracts OP0004 (ALTO study) and OP0325 (long term Followup of ARRIA) https://t.co/FCO80mdHLg https://t.co/sX9u8mUoak

Procalcitonin can be used in the monitoring of infection, but is also high in Stills disease. 89 AOSD pts showed pts w high PCT had more pleuritis, MAS,^LFTs, & correlated w/ Dz activity, CRP, LDH, hi ferritin & normalized w bDMARD Rx. #EULAR2025 abstr #POS1118 https://t.co/NpRA9optd3

"H Syndrome" review of 23 French pts. Autoinflammatory dz due to variants of SLC29A3 gene. Multisystem histiocytic lymphoproliferative disorder of young adults- skin 2/3, sensorineural hearing loss, fever w/ endo & autoimmune dz. Best responses w IL6 inhib. #EULAR2025 Abst https://t.co/F7NGI4TkJS

KORAIL cohort: new RA-ILD progression model (inc. DLCO, ILD pattern/extent, anti-CCP, ± KL-6) stratified risk with high sensitivity & specificity. Adding KL-6 boosted AUC to 0.75. A step toward personalised care in RA-ILD. @RheumNow #EULAR2025 #OP0328 https://t.co/AHqNFw40gk

In real-world PsA, IL-23 inhibitors (guselkumab/risankizumab) showed clinical response in axial/mixed PsA. Best response seen in pts meeting ASAS axial SpA criteria (RR 7.64) & baseline ASDAS-CRP >2.1. Supports role of patient stratification in axial PsA. Abstract#POS0113 https://t.co/qowZZmJOpM

#EULAR2025 Abstr#OP0281 Not just shredding the weight but now also the pain! Another potential benefit of GLP-1 agonists - reducing symptoms of patients with Fibromyalgia. Propensity matched analysis using TrinetX database showed reduction on opiates, fatigue and pain @RheumNow https://t.co/oh6ecJmM5e

Efficacy and Safety of Xeligekimab in AS Dr. Adela Castro reports on abstract OP0102 at the EULAR 2025 meeting in Barcelona, Spain https://t.co/xpzeV0oZOr https://t.co/wmTnFbFcum

Are we missing axial/SIJ lesions in PsA or are we misdiagnosing AxSPA + PSO pts for PsA? 5 register studies including 580+ pts w/ PsA/AxSPA+PSO 1/3 PsA routine care patients had SIJ MRI = SPA 29% Rx SII r-mNY criteria+ of which 38% MRI lesions AxSPA @RheumNow #EULAR2025 https://t.co/DJljlm7T9m

Depression and anxiety in PsA is higher and has more consequences than in general population Swedish and Danish clinical registers 23000+ PsA pts HR 1.4 specialised psychiatric out/ inpatient care vs. general pop HR for psychiatric in patient care numerically higher but ns. No https://t.co/qduMcwGK0S

Prediction of PsA in PSO pts: does it work? First predictive model using mainly clinical data and labs extracted from primary care Performs well in the cohort it was trained w/ but not in validation cohort. Often an issue with prediction models! Needs more granularity than https://t.co/5cVgqfd4fX

‼️Diagnosis of axSpA is clinical -MRI is a tool but still has a lot of limitations. -Improve reports by directly communicating with radiology and be specific on pt clinical info. -Unified algorithms are needed to apply AI in dx of SIJ inflammation on MRI. #EULAR2025 @RheumNow https://t.co/9GR6FsgIcL